ArticleBMC cancer2022

Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.

Aliza Mohd Yacob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.